View Associated Notes
Category 6 - PATHOLOGY SERVICES
66585 - Additional Information
Quantification of laboratory‑based BNP or NT‑proBNP testing in a patient with systemic sclerosis (scleroderma) to assess risk of pulmonary arterial hypertension
Maximum of 2 tests in a 12 month period
Fee: $58.50 Benefit: 75% = $43.90 85% = $49.75
(See para PN.2.5 of explanatory notes to this Category)
Associated Notes
Category 6 - PATHOLOGY SERVICES
PN.2.5
NT-proBNP testing in patients with systemic sclerosis - MBS item 66585
NT-proBNP testing under MBS item 66585 should be performed along with a pulmonary function test (PFT) measuring diffusing capacity for carbon monoxide in accordance with the 2012 Australian Scleroderma Interest Group (ASIG) pulmonary arterial hypertension (PAH) screening algorithm.
Repeat testing within a 12 month period should only be performed for a patient presenting with new symptoms suggestive of PAH since last assessment or a patient that has a borderline NT-proBNP level between 168-209 pg/mL.
Where MBS item 66585 is requested by a medical practitioner (other than a specialist or consultant physician), the request should be made in consultation with a specialist or consultant physician who manages the treatment of the patient.
Related Items: 66585
Legend
- Assist - Addition/Deletion of (Assist.)
- Amend - Amended Description
- Anaes - Anaesthetic Values Amended
- Emsn - EMSN Change
- Fee - Fee Amended
- Renum - Item Number Change (renumbered)
- New - New Item
- NewMin - New Item (previous Ministerial Determination)
- Qfe - QFE Change